Developer docs
API playgroundTry for free, no card

Search company profiles

Elisa Act

Full company profile

uuid000mcis

Namestring
Elisa Act
Legal namestring
ELISA/ACT Biotechnologies (EAB)
Websiteurl
elisaact.com
Company typeenum
Private
Founded yearint
1984
Descriptiontext

ELISA/ACT Biotechnologies (EAB), doing business as Elisa Act, was a privately held specialty diagnostics company founded in 1984 by Russell M. Jaffe, MD, PhD, CCN, NACB and headquartered in Sterling, United States. The company developed and commercialized the patented Lymphocyte Response Assay (LRA) by ELISA/ACT, an ex-vivo laboratory testing platform that directly assesses lymphocyte responses to detect all three types of delayed hypersensitivity reactions to foods and environmental chemicals. This testing methodology provided clinicians with diagnostic insight into immune tolerance and overload, positioning the company within the personalized and functional immunology segment of clinical diagnostics.

The company operated a business-to-business model, serving integrative health practitioners, functional medicine clinicians, and other healthcare providers seeking root-cause diagnostic insights for patients with chronic conditions. Its primary customer base comprised thousands of clinicians who integrated the LRA testing into workflows for uncovering hidden immune triggers. Pricing was not publicly disclosed, and the company maintained a lean operating structure of 1-10 employees. Beyond its core LRA testing service, the company offered a secondary Microbiome Support Protocol combining recommended diagnostic tests with targeted nutraceuticals for gut and immune health.

In 2024, after over 40 years of operation, ELISA/ACT Biotechnologies announced the discontinuation of its operations, with the LRA by ELISA/ACT tests permanently retired. The company has redirected its focus and resources to its sister company, PERQUE Integrative Health, which carries forward Dr. Jaffe's science-based legacy through nutritional solutions and clinical protocols rather than diagnostic testing services. As of the reporting date, the company's operating status is closed.

Short descriptiontext

ELISA/ACT Biotechnologies (Elisa Act) was a Sterling, US-based specialty diagnostics company that operated the patented Lymphocyte Response Assay (LRA) testing platform for healthcare practitioners from 1984 until its 2024 discontinuation, with its legacy now continuing through sister company PERQUE Integrative Health.

Operating statusenum
Closed
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSterling, United States
HQ citystring
Sterling
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
lymphocyte response assays, delayed hypersensitivity testing, functional medicine diagnostics, personalized immunology, ex-vivo immune testing
Industry3 codes
PRIMARYHLAAALAK
Autoimmune & Allergy Diagnostics
SECONDARYHLAKAAAD
Food Allergy Evaluation & Management
SECONDARYHLAGADAA
Bioanalytical Testing (PK/ADA/NAb)
NAICS code1 code
  • Medical Laboratories621511
SIC code1 code
  • Services-Medical Laboratories8071
Product category
Clinical Diagnostic Services
No data
Cost components4 values
Operations, Technology or R&D, Personnel, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 record
1LRA by ELISA/ACT
Description

Patented Lymphocyte Response Assay testing platform that directly assesses lymphocyte responses to detect all three types of delayed hypersensitivity reactions to foods and environmental chemicals.

Core offering1 text field

Elisa Act (ELISA/ACT Biotechnologies) provided the patented Lymphocyte Response Assay (LRA) by ELISA/ACT — an ex-vivo diagnostic test that directly assesses lymphocyte responses to detect all three types of delayed hypersensitivity reactions to foods and environmental chemicals. The test delivered insight into immune tolerance and overload to help clinicians identify root-cause triggers of chronic conditions. The company also offered a Microbiome Support Protocol combining Dr. Jaffe-recommended tests with targeted PERQUE nutraceuticals to address inflammation, gut restoration, and immune balance.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Elisa Act (ELISA/ACT Biotechnologies) operated as a single-core-product company offering the LRA by ELISA/ACT testing platform for personalized immunology. This patented Lymphocyte Response Assay was the company's primary offering for detecting delayed hypersensitivity reactions. The company has announced discontinuation of operations as of the information date, with the LRA by ELISA/ACT tests not returning. A secondary offering, the Microbiome Support Protocol, provides targeted nutraceutical-based support for gut and immune health, linking to their sister company PERQUE Integrative Health for continued service delivery.

Product and service2 records
1LRA by ELISA/ACT
CategoryClinical diagnostic testing service
Description

Patented Lymphocyte Response Assay (LRA) ex-vivo testing that directly assesses lymphocyte responses to detect all three types of delayed hypersensitivity reactions to foods and environmental chemicals, providing insight into immune tolerance and overload. It is used by healthcare practitioners — particularly in integrative and functional medicine — to uncover hidden immune triggers at the root of chronic conditions.

2Microbiome Support Protocol
CategoryClinical protocol
Description

Comprehensive protocol combining Dr. Jaffe-recommended tests and targeted PERQUE nutraceuticals, designed to assess inflammation, repair deficit, support gut restoration, and promote immune balance for patients identified through functional medicine workups.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Specialty lab offering ELISA-based food sensitivity, allergy, and environmental chemical panels via practitioner channels — a near-direct alternative to the LRA by ELISA/ACT for delayed hypersensitivity-style testing.

TypeDirect peer
Description

Specialty clinical lab offering immunology, food sensitivity, and environmental reactivity panels to functional medicine providers. Comparable to ELISA/ACT in target customer (integrative clinicians) and test category (delayed hypersensitivities).

TypeDirect peer
Description

Clinical lab offering food sensitivity, immune reactivity, and related panels through a practitioner-facing model. Overlaps with ELISA/ACT in addressing delayed hypersensitivities and chronic-condition root-cause workups.

TypeBroad incumbent
Description

Large national reference laboratory offering a broad menu of immunology and allergy diagnostics. Provides overlapping capability (allergen/immune testing) but is a mainstream, broad-line incumbent rather than a niche functional-medicine specialist like ELISA/ACT.

TypeDirect peer
Description

Specialty reference lab serving integrative and functional medicine practitioners with immunology, food reactivity, and related panels. Comparable in channel (clinician-direct) and category (immune/food sensitivity diagnostics).

TypeDirect peer
Description

Clinical laboratory providing immune, food sensitivity, and functional medicine testing panels to healthcare practitioners. Closely overlaps ELISA/ACT in customer base (functional/integrative clinicians), testing categories (food and chemical reactivity), and CLIA-style service delivery.

TypeDirect peer
Description

Specialty clinical laboratory offering arrays of immune reactivity and food/chemical sensitivity testing (including gluten, autoimmune, and environmental antigen panels) marketed to functional and integrative medicine practitioners — directly comparable to ELISA/ACT's LRA platform.

8Cell Science Systems (ALCAT Test)
TypeDirect peer
Description

Operator of the ALCAT food and chemical sensitivity test, an ex-vivo cellular assay marketed to clinicians for identifying food/chemical intolerances. Directly competes with ELISA/ACT on the same functional medicine use case of identifying hidden immune reactivity.

TypeBroad incumbent
Description

Major national reference lab offering allergy and immunology panels among its broad testing menu. Overlaps categorically with ELISA/ACT but competes in mainstream clinical channels rather than the integrative/functional medicine niche.

10PERQUE Integrative Health
TypeOthers
Description

Sister company to ELISA/ACT Biotechnologies, now carrying Dr. Jaffe's science-based legacy through nutritional solutions, clinical protocols, and the Microbiome Support Protocol. Not a direct competitor but the closest corporate/strategic entity preserving the founder's immunology work.

Market position
Strengths3 records

Each record includes

Headline, Details, Source

Weaknesses3 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Elisa Act

Clinical Diagnostic Serviceselisaact.com

ELISA/ACT Biotechnologies (Elisa Act) was a Sterling, US-based specialty diagnostics company that operated the patented Lymphocyte Response Assay (LRA) testing platform for healthcare practitioners from 1984 until its 2024 discontinuation, with its legacy now continuing through sister company PERQUE Integrative Health.

What Elisa Act does

ELISA/ACT Biotechnologies (EAB), doing business as Elisa Act, was a privately held specialty diagnostics company founded in 1984 by Russell M. Jaffe, MD, PhD, CCN, NACB and headquartered in Sterling, United States. The company developed and commercialized the patented Lymphocyte Response Assay (LRA) by ELISA/ACT, an ex-vivo laboratory testing platform that directly assesses lymphocyte responses to detect all three types of delayed hypersensitivity reactions to foods and environmental chemicals. This testing methodology provided clinicians with diagnostic insight into immune tolerance and overload, positioning the company within the personalized and functional immunology segment of clinical diagnostics.

The company operated a business-to-business model, serving integrative health practitioners, functional medicine clinicians, and other healthcare providers seeking root-cause diagnostic insights for patients with chronic conditions. Its primary customer base comprised thousands of clinicians who integrated the LRA testing into workflows for uncovering hidden immune triggers. Pricing was not publicly disclosed, and the company maintained a lean operating structure of 1-10 employees. Beyond its core LRA testing service, the company offered a secondary Microbiome Support Protocol combining recommended diagnostic tests with targeted nutraceuticals for gut and immune health.

In 2024, after over 40 years of operation, ELISA/ACT Biotechnologies announced the discontinuation of its operations, with the LRA by ELISA/ACT tests permanently retired. The company has redirected its focus and resources to its sister company, PERQUE Integrative Health, which carries forward Dr. Jaffe's science-based legacy through nutritional solutions and clinical protocols rather than diagnostic testing services. As of the reporting date, the company's operating status is closed.

Elisa Act firmographics

Firmographics
Name
Elisa Act
Legal name
ELISA/ACT Biotechnologies (EAB)
Website
https://elisaact.com
Company type
Private
Founded year
1984
Operating status
Closed
Headcount range
1–10 employees
Short description
ELISA/ACT Biotechnologies (Elisa Act) was a Sterling, US-based specialty diagnostics company that operated the patented Lymphocyte Response Assay (LRA) testing platform for healthcare practitioners from 1984 until its 2024 discontinuation, with its legacy now continuing through sister company PERQUE Integrative Health.
Ownership category
akta.pro rank

Elisa Act industry classification

Industry
Product category
Clinical Diagnostic Services
NAICS
Medical Laboratories (621511)
SIC
Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAAALAK
Autoimmune & Allergy Diagnostics
SECONDARYHLAKAAAD
Food Allergy Evaluation & Management
SECONDARYHLAGADAA
Bioanalytical Testing (PK/ADA/NAb)

Keywords

  • Lymphocyte response assays
  • Delayed hypersensitivity testing
  • Functional medicine diagnostics
  • Personalized immunology
  • Ex-vivo immune testing

Where Elisa Act is headquartered

Location

Headquarters

HQ city
Sterling
HQ country
United States
HQ region
North America

Markets served

Elisa Act business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Operations, Technology or R&D, Personnel, Marketing or Sales

Elisa Act product offering

Product offering

Core offering

Elisa Act (ELISA/ACT Biotechnologies) provided the patented Lymphocyte Response Assay (LRA) by ELISA/ACT — an ex-vivo diagnostic test that directly assesses lymphocyte responses to detect all three types of delayed hypersensitivity reactions to foods and environmental chemicals. The test delivered insight into immune tolerance and overload to help clinicians identify root-cause triggers of chronic conditions. The company also offered a Microbiome Support Protocol combining Dr. Jaffe-recommended tests with targeted PERQUE nutraceuticals to address inflammation, gut restoration, and immune balance.

Product overview

Elisa Act (ELISA/ACT Biotechnologies) operated as a single-core-product company offering the LRA by ELISA/ACT testing platform for personalized immunology. This patented Lymphocyte Response Assay was the company's primary offering for detecting delayed hypersensitivity reactions. The company has announced discontinuation of operations as of the information date, with the LRA by ELISA/ACT tests not returning. A secondary offering, the Microbiome Support Protocol, provides targeted nutraceutical-based support for gut and immune health, linking to their sister company PERQUE Integrative Health for continued service delivery.

Differentiator

Problem solved

Functional benefit

Brands

  • LRA by ELISA/ACT: Patented Lymphocyte Response Assay testing platform that directly assesses lymphocyte responses to detect all three types of delayed hypersensitivity reactions to foods and environmental chemicals.

Products and services

  • LRA by ELISA/ACT Patented Lymphocyte Response Assay (LRA) ex-vivo testing that directly assesses lymphocyte responses to detect all three types of delayed hypersensitivity reactions to foods and environmental chemicals, providing insight into immune tolerance and overload. It is used by healthcare practitioners — particularly in integrative and functional medicine — to uncover hidden immune triggers at the root of chronic conditions.
  • Microbiome Support Protocol Comprehensive protocol combining Dr. Jaffe-recommended tests and targeted PERQUE nutraceuticals, designed to assess inflammation, repair deficit, support gut restoration, and promote immune balance for patients identified through functional medicine workups.

Companies that use Elisa Act

Customer profile

Segments1 record

Ideal customer profiles1 record

Elisa Act technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Elisa Act partnerships and signals

Strategic signal

Scale indicators2 records

Recent moves4 records

Expansion highlights3 records

Elisa Act competitors and assessment

Company assessment

Direct peers

  • US Biotek Laboratories: Specialty lab offering ELISA-based food sensitivity, allergy, and environmental chemical panels via practitioner channels — a near-direct alternative to the LRA by ELISA/ACT for delayed hypersensitivity-style testing.
  • Mosaic Diagnostics (formerly Great Plains Laboratory): Specialty clinical lab offering immunology, food sensitivity, and environmental reactivity panels to functional medicine providers. Comparable to ELISA/ACT in target customer (integrative clinicians) and test category (delayed hypersensitivities).
  • Vibrant Wellness: Clinical lab offering food sensitivity, immune reactivity, and related panels through a practitioner-facing model. Overlaps with ELISA/ACT in addressing delayed hypersensitivities and chronic-condition root-cause workups.
  • Doctor's Data: Specialty reference lab serving integrative and functional medicine practitioners with immunology, food reactivity, and related panels. Comparable in channel (clinician-direct) and category (immune/food sensitivity diagnostics).
  • Genova Diagnostics: Clinical laboratory providing immune, food sensitivity, and functional medicine testing panels to healthcare practitioners. Closely overlaps ELISA/ACT in customer base (functional/integrative clinicians), testing categories (food and chemical reactivity), and CLIA-style service delivery.
  • Cyrex Laboratories: Specialty clinical laboratory offering arrays of immune reactivity and food/chemical sensitivity testing (including gluten, autoimmune, and environmental antigen panels) marketed to functional and integrative medicine practitioners — directly comparable to ELISA/ACT's LRA platform.
  • Cell Science Systems (ALCAT Test): Operator of the ALCAT food and chemical sensitivity test, an ex-vivo cellular assay marketed to clinicians for identifying food/chemical intolerances. Directly competes with ELISA/ACT on the same functional medicine use case of identifying hidden immune reactivity.

Broad incumbents

  • Quest Diagnostics: Large national reference laboratory offering a broad menu of immunology and allergy diagnostics. Provides overlapping capability (allergen/immune testing) but is a mainstream, broad-line incumbent rather than a niche functional-medicine specialist like ELISA/ACT.
  • Laboratory Corporation of America (Labcorp): Major national reference lab offering allergy and immunology panels among its broad testing menu. Overlaps categorically with ELISA/ACT but competes in mainstream clinical channels rather than the integrative/functional medicine niche.

Others

  • PERQUE Integrative Health: Sister company to ELISA/ACT Biotechnologies, now carrying Dr. Jaffe's science-based legacy through nutritional solutions, clinical protocols, and the Microbiome Support Protocol. Not a direct competitor but the closest corporate/strategic entity preserving the founder's immunology work.

Market position

Strengths3 records

Weaknesses3 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

Elisa Act financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Elisa Act leadership team

Management profile

Number of profiles

Elisa Act funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Elisa Act M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Elisa Act

What does Elisa Act do?

Elisa Act (ELISA/ACT Biotechnologies) provided the patented Lymphocyte Response Assay (LRA) by ELISA/ACT — an ex-vivo diagnostic test that directly assesses lymphocyte responses to detect all three types of delayed hypersensitivity reactions to foods and environmental chemicals. The test delivered insight into immune tolerance and overload to help clinicians identify root-cause triggers of chronic conditions. The company also offered a Microbiome Support Protocol combining Dr. Jaffe-recommended tests with targeted PERQUE nutraceuticals to address inflammation, gut restoration, and immune balance.

Is Elisa Act a public or private company?

Elisa Act is a private company. It is classified as founder individual operated bootstrapped and is currently closed.

When was Elisa Act founded?

Elisa Act was founded in 1984. It employs 1 to 10 people.

Where is Elisa Act based?

Elisa Act is headquartered in Sterling, United States, in the North America region.

Who are Elisa Act's main competitors?

Direct peers on record are US Biotek Laboratories, Mosaic Diagnostics (formerly Great Plains Laboratory), Vibrant Wellness, Doctor's Data, Genova Diagnostics, Cyrex Laboratories and Cell Science Systems (ALCAT Test). Broad incumbents are Quest Diagnostics and Laboratory Corporation of America (Labcorp). PERQUE Integrative Health is listed as an others.

Does Elisa Act have an API?

No public API is recorded for Elisa Act.

What industry is Elisa Act in?

Elisa Act's product category is Clinical Diagnostic Services. Its primary akta.pro industry code is HLAAALAK, Autoimmune & Allergy Diagnostics, with a secondary code of HLAKAAAD, Food Allergy Evaluation & Management. Its NAICS code is 621511 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales